Keywords: dream, study, results, position, gsk, avandia, first-line
DREAM study results position GSK's Avandia as first-line treatment for type 2 diabetes
Article | 25 September 2006
UK drug major GlaxoSmithKline's Avandia (rosiglitazone maleate) reduced the risk of prediabetics progressing to full-blown type 2 diabetes 62% relative to placebo, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
